Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy

Antiviral Chemistry and Chemotherapy

Volumn 10, Issue 1, 1999, Pages 1-14

  Daelemans, Dirk ^a   Vandamme, Anne Mieke ^a   De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Gene regulation; HIV; Inhibition

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIVIRUS AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; N (6 AMINOHEXYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N BENZYLGLYCYL N (3 GUANIDINOPROPYL)GLYCYL DEXTRO LYSYL DEXTRO LYSYL DEXTRO ARGINYL DEXTRO PROLINAMIDE; REGULATOR PROTEIN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

DRUG RESISTANCE; GENE CONTROL; GENETIC TRANSCRIPTION; HUMAN IMMUNODEFICIENCY VIRUS; LONG TERMINAL REPEAT; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; TRANSACTIVATION; VIRUS GENE; VIRUS REPLICATION;

EID: 0033028772     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029901000101     Document Type: Review

References (131)

1. Baba M, Okamoto M, Makino M, Kimura Y, Ikeuchi T, Sakaguchi T & Okamoto T (1997) Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives. Antimicrobial Agents and Chemotherapy 41:1250-1255.
2. Baba M, Okamoto M, Kawamura M, Makina M, Higashida T, Takashi T, Kimura Y, Ikeuchi T, Tetsuka T & Okamoto T (1998) Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives. Molecular Pharmacology 53:1097-1103.
3. Baeuerle P & Baltimore D (1988) IκB: a specific inhibitor of the NF-κB transcription factor. Science 242:540-546.
4. Baur A, Harrer T, Peukert M, Jahn G, Kalden JR & Fleckenstein B (1991) Alpha-lipoic acid is an effective inhibitor of human immuno-deficiency virus (HIV-1) replication. Klinische Wohenschrift 69:722-724.
5. Bielinska A, Shivdasani RA, Zhang L & Nabel GJ (1990) Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science 250:997-1000.
6. Bieniasz PD, Grdina TA, Bogerd HP & Cullen BR (1998) Recruitment of a protein complex containing tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO Journal 17:7056-65
7. Biswas DK, Ahlers CM, Dezube B & Pardee AB (1993a) Pentoxifylline inhibits HIV-1 LTR-driven gene expression by blocking NF-κB action. Journal of Acquired Immune Deficiency Syndromes 6:778-786.
8. Biswas DK, Ahlers CM, Dezube BJ & Pardee AB (1993b) Cooperative inhibtion of NF-κB and Tat-induced superactivation of human immunodeficiency virus type 1 long terminal repeat. Proceedings of the National Academy of Sciences, USA 90:11044-11048.
9. Biswas DK, Ahlers CM, Dezube B.J & Pardee AB (1994) Pentoxifylline and other protein kinase C inhibtors down-regulate HIV-LTR NF-κB induced gene expression. Molecular Medicine 1:31-34.
10. Bohan CA, Kashanchi F, Ensoli B, Buonaguro L, Boris-Lawrie KA, & Brady JN (1992) Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro. Gene Expression 2:391-407.
11. Borgatti P, Zauli G, Cantley LC & Capitani S (1998) Extracellular HIV-1 Tat protein induces a rapid and selective activation of protein kinase C (PKC)-α and -ε and -ξ isoforms in PC12 cells. Biochemical and Biophysical Research Communications 242:332-337.
12. Chandra A, Demirhan I, Arya SK & Chandra P (1988) D-Penicillamine inhibits transactivation of human immunodeficiency virus type-1 (HIV-1) LTR by transactivator protein. FEBS Letters 236:282-286.
13. Chang HC, Samaniego F, Nair BC, Buonaguro L & Ensoli B (1997) HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 11:1421-1431.
14. Choudhury I, Wang J, Rabson AB, Stein S, Pooyan S, Stein S & Leibowitz MJ (1998) Inhibition to HIV-1 replication by a Tat RNA-binding domain peptide analog. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 17:104-111.
15. + T cells using a combination of cytokines. Journal of Experimental Medicine 188:83-91.
16. Cochrane AW, Jones KS, Beidas S, Dillon PJ, Skalka AM & Rosen CA (1991) Indentification and characterization of intragenic sequences which repress human immunodeficiency virus structural gene expression. Journal of Virology. 65:5305-5313.
17. Crooke ST (1998) An overview of progress in antisense therapeutics. Antisense Nucleic Acid Drug Devlopment 8:115-122.
18. Cruikshank WW, Doctrow SR, Falvo MS, Huffman K, Maciaszek J, Viglianti G, Raina J, Kornfeld H & Malfroy B (1997) A lipidated anti-Tat antibody enters living cells blocks HIV-1 viral replication. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 14:193-203.
19. Cullen BR (1991) Regulation of HIV-1 gene expression. FASEB Journal 5:2361-2368.
20. Cullen BR (1995) Regulation of HIV gene expression. AIDS 9:19-32.
21. Cullen BR (1998) HIV-1 auxiliary proteins: making connection in a dying cell. Cell 93:685-692.
22. Daelemans D, Esté JA, Witvrouw M, Pannecouque C, Jonckheere H, Aquaro S, Perno C-F, De Clercq E & Vandamme A-M (1997) S-adenosylhomocysteine hydrolase inhibitors interfere with the replication of human immunodeficiency virus type 1 through inhibtion of the LTR transactivation. Molecular Pharmacology 52:1157-1163.
23. 3 inhibits nuclear factor-κB activiation by 12-O-teradecanoylphorbol-13-acetate but not by tumor necrosis factor-α or interleukin 1α. Cancer Research 55:4844-4849.
24. Dayton AI, Sodroski JG, Rosen CA, Goh WC & Haseltine WA (1986) The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell 44:941-947.
25. De Clercq E (1995) Antiviral therapy for human immunodeficiency virus infections. Clinical Microbiology Reviews 8:200-239.
26. De Clercq E (1997) Virus replication: target functions and events for virus-specific inhibitors. In Antiviral Agents and Human Viral Diseases, pp 1-44. Edited by GJ Galasso, RJ Whitley and TC Merigan, Philadelphia: Lippincott-Raven.
27. Dezube BJ & Lederman MM (1995) Pentoxifylline for the treatment of HIV infection and its complications. Journal Cardiovascular Pharmacology 25:S139-S142.
28. Doranz BJ, Grovit-Ferbas K, Sharron MP, Mao SH, Daar ES, Doms RW & O'Brien WA (1997) A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as and HIV-1 coreceptor. Journal of Experimental Medicine 186:1395-1400.
29. Dropulic B & Jeang KT (1994) Intraclellular susceptibility to ribozymes in a tethered substrate-ribozyme provirus model is not predicited by secondary structures of human immunogeficiency virus type 1 RNAs in vitro. Antisense Research and Development 4:217-212.
30. Duan L, Bagasra O, Laughlin MA, Oakes JW & Pomerantz RJ (1994) Potent inhibtion of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. Proceedings of the National Academy of Sciences, USA 91:5075-5079.
31. Emaliani S, Fischle W, Ott M, VanLint C, Amella CA & Verdin E (1998) Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line. Journal of Virology 72:1666-1670 (1998)
32. Emerman M & Malim MH (1998) HIV-1 regulatory/accessory genes: keys to unraveling viral host cell biology. Science 280:1880-1884.
33. Esté JA, Witvrouw M, Tu J, Desmyter J, De Clercq E & Vandamme A-M (1995) Inhibition of HIV type 1 Tat-mediated trans-activation by oncostatin M in HLtat cells. AIDS Research and Human Retroviruses 11:1355-1358.
34. Fabbri S, Prometra C, Broggini M, & D'incalci M (1993) Differential inhibtion of DNA binding of transcription factors NF-kB and OTF-1 by nitrogen mustard and quinacrine mustard: transcriptional implications. Carcinogenesis 14:1963-1967.
35. Fazely F, Dezube BJ, Allen-Ryan J, Pardee AB & Ruprecht RM (1991) Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in cultured T cells. Blood 77:1653-1656.
36. Feinberg MB, Baltimore D, & Frankel AD (1991) The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcription elongation. Proceedings of the National Academy of Sciences, USA 88:4045-4049.
37. Felber BK, Hadzopoulou-Cladaras M, Cladaras C, Copeland T & Pavlakis GN (1989) Rev protein of HIV-1 affects the stability and transport of viral mRNA. Proceedings of the National Academy of Sciences, USA 86:1495-1499.
38. Fenster SD, Wagner RW, Froehler BC & Chin DJ (1994) Inhibition of human immunodeficiency virus type 1 env expression by C-5 propyne oligonucleotides specific for Rev-response element stem loop V. Biochemistry 33:8391-8398.
39. Fisher AG, Feinberg MB, Fosephs SF, Harper ME, Marselle LM, Reyes G, Gonda MA, Aldovini A, Debouk C, Gallo RC & Wong-Staal F (1986) The trans-activator gene of HTLV-III is essential for virus replication. Nature 320:367-371.
40. Gait MJ, & Karn J (1993) RNA recognition by the human immunodeficiency virus Tat and Rev proteins. Trends in Biochemical Sciences 18:255-259.
41. Garcia JA, Harrich D, Soultanakis E, Wu F, Mitsuyasu R & Gaynor RB (1989) Human immunodeficiency virus type 1 LTR TAT and TAR region sequences required for transcriptional regulation. EMBO Journal 8:795-778.
42. Gaynor RB (1995) Regulation of HIV-1 gene expression by the transactivator protein tat. In Transacting functions of human retroviruses pp 55-77. Edited by A Srinivasan and PK Vogt. Heidelberg: Springer-Verlag.
43. Gnabre JN, BradyJN, Clanton DJ, Ito Y, Dittmer J, Bates RB & Huang RCC (1995) Inhibiton of human immunodeficiency virus type 1 transcription and replication by DNA sequence-selective plant lingans. Proceedings of the National Academy of Sciences, USA 92:11239-11243.
44. Graham GJ & Maio JJ (1990) RNA transcripts of the human immunodeficiency virus transactivation response element can inhibit action of the viral transactivator. Proceedings of the National Academy of Sciences, USA 87:5817-5821.
45. Green M, Ishino M & Loewenstein PM (1989) Mutational analysis of HIV-1 Tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR -driven gene expression. Cell 58:215-223.
46. Hammarskjold M-L, Heimer J, Hammarskjold B, Sanwan I, Albert L, & Rekosh D (1989) Regulation of human immunodeficiency virus env expression by the rev gene product. Journal of Virology 63:1959-1966.
47. Hamy F, Felder ER, Heizmann G, Lazdins J, Aboul-Ela F, Varani G, Karn J & Klimkait T (1997) An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proceedings of the National Academy of Sciences, USA 94:3548-3553.
48. Hamy F, Brondani V, Flörsheimer A, Stark W, Blommers MJJ & Klimkait T (1998) A new class of HIV-1 Tat antagonists acting through Tat-TAR inhibition. Biochemistry 37:5086-5095.
49. Hermann CH, & Rice AP (1995) Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor. Journal Virology 69:1612-1620.
50. Hsu M-C, Schutt AD, Holly M, Slice LW, Sherman MI, Richman DD, Potash MJ, & Volsky DJ (1991) Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist. Science 254:1799-1802.
51. Hsu M-C, Schutt AD, Holly M, Slice LW, Sherman MI, Richman D.D, Potash MJ & Volsky DJ (1992) Discovery and characterization of an HIV-1 Tat antagonist. Biochemical Society Transactions 20:525-531.
52. Hsu M-C, Dhingra U, Early JV, Holly M, Keith D, Nalin CM, Richou AR, Schutt AD, Tam SY, Potash MJ, Volsky DJ & Richman DD (1993) Inhibition of type 1 human immunodeficiency virus by a Tat antagonist to which the virus remains sensitive after prolonged exposure in vitro. Proceedings of the National Academy of Sciences, USA 90:6395-6399.
53. Inouye RT, Du B, Doldt-Houle D, Ferrante A, Park IW, Hammer SM, Duan L, Groopman JE, Pomerantz RJ & Terwilliger EF (1997) Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vector. Journal of Virology 71:4071-4078.
54. Jakobovits A, Rosenthal A & Capon D (1990) Trans-activation of the HIV-1 LTR-directed gene expression by tat requires protein kinase C. EMBO Journal 9:1165-1170.
55. Jeyaseelan R, Kurabayashi M & Kedes L (1996) Doxorubicin inhibts Tat-dependent transactivation of HIV type 1 LTR. AIDS Research and Human Retroviruses 12:569-576.
56. Jiang M-C, Lin J-K & Chen SS-L (1996) Inhibition fo HIV-1 Tat-mediated transactivation by quinacrine and chloroquine. Biochemical and Biophysical Research Communications 226:1-7.
57. Jones KA & Peterlin BM (1994) Control of RNA initiation and elongation at the HIV-1 promoter. Annual Review of Biochemistry 63:717-743.
58. Jones KA, Kadonaga JT, Luciw PA & Tjian R (1986) Activation of the AIDS retrovirus promoter by the cellular transcription factor, Sp1. Science 232:755-759.
59. Kao S-Y, Calman AF, Luciw PA, & Peterlin BM (1987) Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature 330:489-493.
60. Kaufman JD, Valandra G, Roderiquez G, Bushar G, Giri C, and Norcross MA (1987) Phorbol ester enhances human immunodeficiency virus-promoted gene expression and acts on a repeated 10-base-pair functional enhancer element. Molecular Cell Biology 7:3759-3766.
61. Kim JH, McLinden RJ, Mosca JD, Vahey MT, Greene WC & Redfield RR (1996) Inhibition of HIV replication by sense and antisense rev response elements in HIV-based retroviral vectors. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 12:343-351.
62. Kim S, Byrn R, Groopman JE, & Baltimore D (1989) Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. Journal of Virology 63:3708-3713.
63. Kingsman SM, & Kingsman AJ (1996) The regulation of human immunodeficiency virus type 1 gene expression. European Journal of Biochemistry 240:491-507.
64. Kira T, Hashimoto K, Baba M, Okamoto T & Shigeta S (1996) 2-Glycineamide-5-chlorophenyl 2-pyrryl ketone, a non-benzodiazepin Tat antagonist, is effective against acute and chronic HIV-1 infections in vitro. Antiviral Research 32:55-62.
65. Kopp E & Ghosh S (1994) Inhibtion of NF-κB by sodium salicylate and aspirin. Science 265:956-959.
66. Kumar S, Orsini MJ, Lee JC, McDonnell PC, Debouck C & Young PR (1996) Activation of the HIV-1 long terminal repeat by cytokines and environmental stress requires an active CSBP/p38 MAK kinase. Journal of Biological Chemistry 271:30864-30869.
67. Lapidot A, Ben-Asher E & Eisenstein M (1995) Tetrahydropyrimidine derivatives inhibit binding of a Tat-like, arginine-containing peptide, to HIV TAR RNA in vitro. FEBS Letters 367:33-38.
68. Laspia MF, Rice AP & Mathews MB (1989) HIV-1 Tat protein increases transcription initiation and stabilizes elongation. Cell 59:283-292.
69. Lee M-O, Hobbs PD, Zhang X-K, Dawson MI & Pfahl M (1994) A synthetic retinoid antagonist inhibts the human immunodeficiency irus type 1 promoter. Proceedings of the National Academy of Sciences, USA 91:5632-5636.
70. Lee R, Beauparlant P, Elford H, Ponka P & Hiscott J (1997) Selective inhibition of IκBα phosphorylation and HIV-1 LTR directed gene expression by novel antioxidant compounds. Virology 234:277-290.
71. Lee SW, Gallardo HF, Gilboa E & Smith C (1994) Inhibition of human immunodeficiency virus type 1 human in T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain. Journal of Virology 68:8254-8264.
72. Leung DW, Peterson PK, Weeks R, Gekker G, Chao CC, Kaplan AH, Balantac N, Tompkins C, Underiner GE, Bursten S, Harris W, Bianco JA & Singer JW (1995) CT-2567, an inhibitor of phospholipid signaling, suppresses constitutive and induced expression of human immunodeficiency virus. Proceedings of the National Academy of Sciences, USA 92:4813-4817.
73. Li CJ, Zhang LJ, Dezube BJ, Crumpacker CS & Pardee AB (1993) Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proceedings of the National Academy of Sciences, USA 90:1839-1842.
74. Lisziewicz J, Sun D, Smythe J, Lusso P, Lori F, Louie A, Markham P, Rossi J, Reitz M & Gallo R (1993) Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proceedings of the National Academy of Sciences, USA. 90:8000-8004.
75. Lo KMS, Biasolo MA, Dehni G, Palú G & Haseltine, WA (1992) Inhibition of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA. Virology 227:431-438.
76. Luciw PA (1996) Human immunodeficiency viruses and their replication. In Fields Virology. Edited by BN Fields, DM Knipe, PM Howley, RM Chanock, JL Melnick, TP Monath, B Roizman and SE Straus. Philadelphia Lippincott-Raven.
77. Malim MH, Freimuth WW, Liu J, Boyle TJ, Lyerly HK, Cullen BR & Nabel GJ (1992) Stabel expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. Journal of Experimental Medicine 176:1197-1201.
78. Mann DA & Frankel AD (1991) Endocytosis and targeting of exogenous HIV-1 Tat protein. EMBO Journal 10:1733-1739
79. Mayers DL, Mikovits JA, Joshi B, Hewlett IK, Estrada JS, Wolfe AD, Garcia GE, Doctor BP, Burke DS, Gordon RK, Lane JR & Chiang P (1995) Anti-human immunodeficiency virus 1 (HIV-1) activities of 3-deazaadenosine analogues: increased potency against 3′-azido-3′-deoxythymidine-resistant HIV-1 strains. Proceedings of the National Academy of Sciences, USA 92:215-219.
80. Merin JP, Matsyama M, Kira T, Baba M, & Okamoto T (1996) Alpha-lipoic acid blocks HIV-1 LTR dependent exprezsion of hygromicin resistance in THP-1 stable transformants. FEBS Letters 394:9-13.
81. Mhashilkar AM, Biswas DK, La Vecchio J, Pardee AB & Marasco WA (1997) Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-κB antagonists. Journal of Viroogy 71:6486-6494.
82. Michne WF, Schroeder JD, Bailey TR, Neumann HC, Cooke D, Young DC, Hughes JV, Kingsley SC Ryan KA, Putz HS, Shaw LJ & Dutko FJ (1995) Keto/enol epoxy steroids as HIV-1 Tat inhibitors: structure-activity relationships and pharmacophore localization. Journal of Medicinal Chemistry 38:3197-3206.
83. Mihm S, Ennen J, Pessara UK, Kurth R & Droge W (1991) Inhibition of HIV-1 replication and NF-κB activity by cysteine and cysteine derivatives. AIDS 5:497-503.
84. Mole L, Margolis D, Ghotbi L & Holodniy M (1994) The use of pentoxifylline alone in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 7:519-521.
85. Nakashima H & Yamamoto N (1987) Inhibition by doxorubicin of human immuno-deficiency virus (HIV) infection and replication in vitro. Journal of Antibiotics 40:396-399.
86. Nottet HS, Moelans II, de Vos NM, de Graaf L, Visser MR & Verhoef J (1997) N-acetyl-L-cysteine-induced up-regulation of HIV-1 gene expression in monocyte-derived macrophages correlates with increased NF-κB DNA binding activity. Journal of Leukocyte Biology 61:33-39.
87. O'Brien WA, Sumner-Smith M, Mao S-H, Sadeghi S, Zhao J-Q & Chen ISY (1996) Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions. Journal of Virology 70:2825-2831.
88. Parada CA, & Roeder RG (1996) Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain. Nature 384:375-378.
89. Pearson L, Garcia J, Wu F, Modesti N, Nelson J & Gaynor R (1990) A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat. Proceedings of the National Academy of Sciences, USA 87:5079-5083.
90. Pessler F, & Hermandez N (1998) The HIV-1 inducer of short transcripts activates the synthesis of 5,6-dichloro-1-beta-D-benzimidazole-resistant short transcripts in vitro. Journal of Biological Chemistry 273:5375-5384.
91. Pomerantz RJ, Seshamma T, & Tono D (1992) Efficient replication of human immunodeficiency virus type 1 requires a threshold level of Rev: potential implications for latency. Journal of Virology 66:1809-1813.
92. Prochaska HJ, Fernandes CL, Pantoja RM & Chavan SJ (1996) Inhibition of human immunodeficiency virus type 1 long terminal repeat-driven transcription by an in vivo metabolite of oltipraz: implications for antiretroviral therapy. Biochemical and Biophysical Research Communications 221:548-553.
93. Qatsha KA, Rudolph C, Marmé D, Schächtele C & May WS (1993) Gö 6976, a selective inhibitor of protein kinase C, is a potent antagonist of human immunodeficiency virus 1 induction from latetn/low-level-producing reservoir cells in vitro. Proceedings of the National Academy of Sciences, USA 90:4674-4678.
94. Qian-Cutrone J, Huang S, Trimble J, Li H, Lin PF, Alam M, Klohr SE & Kadow KF (1996a) Niruriside, a new HIV Rev/RRE binding inhibitor from Phyllanthus niruri. Journal of Natural Products 59:169-199.
95. Qian-Cutrone J, Huang S, Chang LP, Pirnik DM, Klohr SE, Dalterio RA, Hugill R, Lowe S, Alam M & Kadow KF (1996b) Harziphilone and fleephilone, two new Rev/RRE binding inhibitors produced by Trichoderma harzianum Journal of Antibiotics 49:990-997.
96. Raju PA, Herzenberg LA, Herzenberg LA., & Roederer M (1994) Glutathione precursor and antioxidant activities of N-acetylcysteine and oxothiazolidine carboxylate compared in in vitro studies of HIV replciation. AIDS Research and Human Retroviruses 10:961-967.
97. Ratmeyer L, Zapp ML, Green MR, Vinayak R, Kumar A, Boykin & Wilson WD (1996) Inhibition of HIV-1 Rev/RRE interaction by diphenylfuran derivatives. Biochemistry 35:13689-13696.
98. Reines D, Conaway JW & Conaway RC (1996) The RNA polymerase II general elongation factors. Trends in Biochemical Sciences 21:351-355
99. Roederer M, Staal FJ, Raju PA, Ela SW, Herzenberg LA & Herzenberg LA (1990) Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine. Proceedings of the National Academy of Sciences, USA 87:4884-4888.
100. Rosen CA, Terwilliger E, Dayton A, Sodroski JG, & Haseltine WA (1988) Intragenic cis-acting art gene-responsive sequences of the human immunodeficiency virus. Proceedings of the National Academy of Sciences, USA 85:2071-2075.
101. Sarver N, Canbtin EM, Chang PS, Zaia JA, Ladne PA, Stephens DA & Rossi JJ (1990) Ribozymes as potential anti-HIV-1 therapeutic agents. Science 247:1222-1225.
102. Schreck R, Rieber P & Baeuerle PA (1991) Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO Journal 10:2247-2258.
103. Schwartz S, Felber BK & Pavlakis GN (1992) Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. Journal of Virology 66:150-159.
104. Sczakiel G, Oppenländer M, Rittner K & Pawlita M (1992) Tat- and Rev-directed antisense RNA expression inhibits and abolishes replication of human immunodeficiency virus type 1: a temporal analysis. Journal of Virology 66:5576-5581.
105. Sekkaï D, Guittet O, Lemaire G, Tenu J-P & Lepoivre M (1997) Inhibition of nitric oxide synthase expression and activity in macrophages by 3-hydroxyanthranilic acid, a tryptophan metabolite. Archives of Biochemistry and Biophysics 340:117-123.
106. Sheldon M, Ratnasabapathy R & Hermandez N (1993) Characterization of the inducer of short transcripts, a human immunodeficiency virus type 1 transcriptional element that activates the synthesis of short RNAs. Molecular Cell Biology 13:1251-1263.
107. Shoji S, Furuishi K, Misumi S, Miyazaki T, Kino M & Yamataka K (1994) Thiamine disulfide as a potent inhibitor of human immunodeficiency virus (type-1) production. Biochemical and Biophysical Research Communications 205:967-975.
108. Sieweke MH, Tekotte H, Jarosch U & Graf T (1998) Cooperative interaction of Ets-1 with USF-1 required for HIV-1 enhancer activity in T cells. EMBO Journal 17:1728-1739.
109. Staal FJ, Roederer M, Raju PA, Anderson MT, Ela SW, Herzenberg LA & Herzenberg LA (1993) Antioxidants inhibit stimulation of HIV transcription. AIDS Research and Human Retroviruses 9:299-306.
110. Steinaa L, Sørensen AM, Nielsen JO & Hansen J-ES (1994) Antibody to HIV-1 Tat protein inhibits the replication of virus in culture. Archives of Virology 139:263-271.
111. Sullenger BA, Gallardo JF, Ungers GE & Gilboa E (1990) Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 63:601-608.
112. Sumner-Smith M (1995) HIV trans-activation inhibitors: an unproven promise. International Antiviral News 3:109-110.
113. Sumner-Smith M, Zheng Y, Zhang YP, Twist EM & Climie SC (1995) Antiherpetic activities of N-alpha-acetyl-nona-D-arginine amide acetate. Drugs under Experimental Clinical Research 21:1-6.
114. Suzuki YJ, Aggarwal BB & Packer L (1992) a-Lipoic acid is a potent inhibitor of NF-kB activation in human T cells. Biochemical and Biophysical Research Communications 189:1709-1715.
115. Turpin JA, Buckheit RW, Jr, Derse D, Hollingshead M, Williamson K, Palamone C, Osterling MC, Hill SA, Graham L, Schaeffer CA, Bu M, Huang M, Cholody WM, Michejda CJ & Rice WG (1998) Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription. Antimicrobial Agents and Chemotherapy 42;487-494.
116. Ulich C, Harrich D, Estes P & Gaynor RB (1996) Inhibition of human immunodeficiency virus type 1 replication is enhanced by a combination of transdominant Tat and Rev proteins. Journal of Virology 70:4871-4876.
117. Vandamme A-M, Van Vaerenbergh K & De Clercq E (1998) Anti-human immunodeficiency virus drug combination strategies. Antiviral Chemistry and Chemotherapy 9:187-203.
118. Vandendriessche T, Chuah MKL, Chiang L, Chang H-K, Ensoli B & Morgan RA (1995) Inhibition of clinical human immunodeficinecy virus (HIV) type 1 isolates in primary CD4-T lymphocytes by retroviral vectors expressing anti-HIV genes. Journal of Virology 69:4045-4052.
119. Veschambre P, Simard P & Jalinot P (1995) Evidence for functional interaction between the HIV-1 Tat transactivator and the TATA box binding protein in vivo. Journal of Molecular Biology 250:169-180.
120. Wang S, Huber PW, Cui M, Czarnik AW & Mei H-Y (1998) binding of neomycin to the TAR element of HIV-1 RNA induces dissociation of Tat protein by and allosteric mechanism. Biochemistry 37:5549-5557.
121. Wang Y, Hamasaki K & Rando RR (1997) Specificity of aminoglycoside binding to RNA constructs derived from the 16S rRNA decoding region and the HIV-RRE activator region. Biochemistry 36:768-779.
122. Wei P, Garber ME, Fang S-M, Fischer WH & Jones KA (1998) A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92:451-462.
123. Werstuck G, Zapp ML & Green MR (1996) A non-canoical base pair within the human immunodeficiency virus rev-responsive element is involved in both rev and small molecule recognition. Chemical Biology 3:129-137.
124. Witvrouw M, Pauwels R, Vandamme A-M, Schols D, Reymen D, Yamamoto M, Desmyter J & De Clercq E (1992) Cell type-specific anti-human immunodeficiency virus type 1 activity of the transactivation inhibitor Ro5-3335. Antimicrobial Agents and Chemotherapy 36:2628-2633.
125. Witvrouw M, Daelemans D, Pannecouque C, Neyts J, Andrei G, Snoeck R, Vandamme A-M, Balzarini J, Desmyter J, Baba M & De Clercq E (1998) Broad-spectrum antiviral activity and mechanism of antiviral action of the fluoroquinolone derivative K-12. Antiviral Chemistry and Chemotherapy 9:123-133.
126. Wolff B, Sanglier JJ & Wang Y (1997) Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chemical Biology 4:139-147.
127. Yasui H, Butscher W, Cohen M, Spriggs N, Wersto R, Kohn EC, Liotta L, & Gardner K (1997) Selective inhibition of mitogen-induced transactivation of the HIV long terminal repeat by carboxyamidotriazole. Journal of Biological Chemistry 272:28762-28770.
128. Zaia JA, Rossi JJ, Murakawa GJ, Spallone PA, Stephens DA, Kaplan BE, Eritja R, Wallace RB, & Cantin EM (1998) Inhibition of human immunodeficiency virus by using an oligonucleoside methylphosphonate targetd to the tat-3 gene. Journal of Virology 62:3914-3917.
129. Zapp ML, Stern S & Green MR (1993) Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production. Cell 74:969-978.
130. Zapp ML, Young DW, Kumar A, Singh R, Boykin DW, Wilson WD & Green MR (1997) Modulation of the Rev/RRE interaction by aromatic heterocyclic compounds. Bioorganic and Medicinal Chemistry 5:1149-1155.
131. Zhu Y, Pe'ery T, Peng J, Ramanathan Y, Marshall N, Marshall T, Amendt B., Mathews MB & Price DH (1997) Transcription elongation factor P-TEFb is required for HIV-1 Tat transactivation in vitro. Genes and Development 11:2622-2632